Autoantibodies and gastrointestinal symptoms in infertile women in relation to in vitro fertilization

DSpace Repository

Autoantibodies and gastrointestinal symptoms in infertile women in relation to in vitro fertilization

Overview

Detailed record

dc.contributor.author Hammar, Oskar
dc.contributor.author Roth, Bodil
dc.contributor.author Bengtsson, Mariette
dc.contributor.author Mandl, Thomas
dc.contributor.author Ohlsson, Bodil
dc.date.accessioned 2014-02-12T10:26:19Z
dc.date.available 2014-02-12T10:26:19Z
dc.date.issued 2013 en_US
dc.identifier.issn 1471-2393 en_US
dc.identifier.uri http://hdl.handle.net/2043/16855
dc.description.abstract BACKGROUND: Prior reports suggest a link between gonadotropin-releasing hormone (GnRH) and gastrointestinal function. The aim of the study was to prospectively investigate women subjected to in vitro fertilization (IVF) using the GnRH analog buserelin, taking into account gastrointestinal symptoms and antibody development against buserelin, GnRH, luteinizing hormone (LH), and their receptors. METHODS: Gastrointestinal symptoms were registered by the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) before and after IVF treatment, and five years later. Health-related quality of life was evaluated by the 36-item Short-Form questionnaire (SF-36). ELISA was used for antibody analyses before and after treatment. Data were compared with women from the general population. RESULTS: In total, 124 patients were investigated before and after IVF, and 62 were re-evaluated after five years. Buserelin treatment led to significant impairment of constipation (p = 0.004), nausea and vomiting (p = 0.035), psychological well-being (p = 0.000), and the intestinal symptoms' influence on daily life (p = 0.027). At 5-year follow-up, abdominal pain was worsened (p = 0.041), but psychological well-being was improved (p = 0.036), compared to prior treatment, and 15% had an observable deterioration in gastrointestinal symptoms. None developed severe dysmotility. Patients had higher prevalence of IgG antibodies against LH (p = 0.001) and its receptor (p = 0.016), and IgM antibodies against the GnRH receptor (p = 0.001) prior treatment compared with controls, but no antibody development was observed after IVF. CONCLUSION: Patients experience gastrointestinal symptoms during buserelin treatment, and abdominal pain is still increased after five years, but buserelin does not increase antibody formation against GnRH, LH or their receptors. en_US
dc.format.extent 9
dc.language.iso eng en_US
dc.publisher BioMed Central en_US
dc.subject Abdominal pain en_US
dc.subject Gastrointestinal symptoms en_US
dc.subject Gonadotropin-releasing hormone en_US
dc.subject In vitro fertilization en_US
dc.subject Luteinizing hormone en_US
dc.subject.classification Medicine en_US
dc.title Autoantibodies and gastrointestinal symptoms in infertile women in relation to in vitro fertilization en_US
dc.type Article, peer reviewed scientific en_US
dc.contributor.department Malmö University. Faculty of Health and Society en_US
dc.contributor.department Malmö University. Care Science (VV) en_US
dc.identifier.doi 10.1186/1471-2393-13-201 en_US
dc.subject.srsc Research Subject Categories::MEDICINE en_US
dc.identifier.url http://www.biomedcentral.com/1471-2393/13/201
dc.relation.ispartofpublication BMC Pregnancy and Childbirth;
dc.relation.ispartofpublicationvolume 13 en_US
dc.format.artNo 201
mahlocal.rights.oaType bronze
mahlocal.rights.oaType gold
mahlocal.rights.oaType green
 Find Full text Files for download
Icon

This item appears in the following Collection(s)

Overview

Search


Browse

My Account

Statistics